- Home
- WNEB vs ACRV Comparison
WNEB vs ACRV Comparison
Compare WNEB & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNEB
- ACRV
- Stock Information
- Founded
- WNEB 1853
- ACRV 2018
- Country
- WNEB United States
- ACRV United States
- Employees
- WNEB N/A
- ACRV N/A
- Industry
- WNEB Savings Institutions
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- WNEB Finance
- ACRV Health Care
- Exchange
- WNEB Nasdaq
- ACRV Nasdaq
- Market Cap
- WNEB 191.1M
- ACRV 170.3M
- IPO Year
- WNEB N/A
- ACRV 2022
- Fundamental
- Price
- WNEB $9.06
- ACRV $5.65
- Analyst Decision
- WNEB Hold
- ACRV Strong Buy
- Analyst Count
- WNEB 3
- ACRV 5
- Target Price
- WNEB $8.50
- ACRV $22.40
- AVG Volume (30 Days)
- WNEB 41.5K
- ACRV 50.9K
- Earning Date
- WNEB 01-28-2025
- ACRV 11-13-2024
- Dividend Yield
- WNEB 3.08%
- ACRV N/A
- EPS Growth
- WNEB N/A
- ACRV N/A
- EPS
- WNEB 0.52
- ACRV N/A
- Revenue
- WNEB $72,500,000.00
- ACRV N/A
- Revenue This Year
- WNEB N/A
- ACRV N/A
- Revenue Next Year
- WNEB $6.24
- ACRV N/A
- P/E Ratio
- WNEB $17.59
- ACRV N/A
- Revenue Growth
- WNEB N/A
- ACRV N/A
- 52 Week Low
- WNEB $6.00
- ACRV $3.19
- 52 Week High
- WNEB $10.08
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- WNEB 49.99
- ACRV 41.71
- Support Level
- WNEB $8.51
- ACRV $5.36
- Resistance Level
- WNEB $9.22
- ACRV $6.00
- Average True Range (ATR)
- WNEB 0.17
- ACRV 0.52
- MACD
- WNEB 0.01
- ACRV -0.01
- Stochastic Oscillator
- WNEB 68.75
- ACRV 17.74
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the Company's revenues, profits, and assets are derived by the Bank from banking products and services.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.